INTRACAVERNOUS PHARMACOTHERAPY FOR IMPOTENCE - SELECTION OF APPROPRIATE AGENT AND DOSE

We performed a retrospective analysis of 101 impotent patients using i ntracavernous self-injections as primary therapy for vasculogenic impo tence. A total of 70 patients used an average of 5.58 mug. prostagland in E1 (95% confidence interval 4.83 to 6.34 mug.) as a single agent, a nd 31 injected 0.40 ml. (95% confidence interval 0.342 to 0.457 ml.) o f a combination of papaverine (12 mg./ml.), phentolamine (1 mg./ml.) a nd prostaglandin E1 (9 mug./ml.). We describe the procedure to establi sh the dosage for home use and discuss the implications of the low dos ages relative to previous reports.